JPH06500994A - 抗うつ剤としての１−置換フェノキサチイン誘導体 - Google Patents

抗うつ剤としての１−置換フェノキサチイン誘導体

Info

Publication number: JPH06500994A
Authority: JP; Japan
Prior art keywords: compound; dioxide; phenoxathiin; hydroxyethyl; formulation
Prior art date: 1990-09-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP3515263A

Other languages

English (en)

Japanese (ja)

Inventor

マッギー，ダニエル　ピーター　クロード

ホワイト，ヘレン　リング

ジョンソン，トーマス　ユージン

ハレルソン，ジェーン　クロフト

ハーフェニスト，モルトン

リーブス，マーク　デビッド

チャンドラスリン，ピサル

Original Assignee

ザ　ウエルカム　ファウンデーション　リミテッド

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-09-17

Filing date

1991-09-16

Publication date

1994-01-27

1991-09-05 Priority claimed from GB919118955A external-priority patent/GB9118955D0/en

1991-09-16 Application filed by ザ　ウエルカム　ファウンデーション　リミテッド filed Critical ザ　ウエルカム　ファウンデーション　リミテッド

1994-01-27 Publication of JPH06500994A publication Critical patent/JPH06500994A/ja

Status Pending legal-status Critical Current

Links

239000000935 antidepressant agent Substances 0.000 title claims description 4
229940005513 antidepressants Drugs 0.000 title claims description 4
-1 1-Substituted phenoxathiin Chemical class 0.000 title description 8
150000001875 compounds Chemical class 0.000 claims description 51
239000000203 mixture Substances 0.000 claims description 43
102000010909 Monoamine Oxidase Human genes 0.000 claims description 23
108010062431 Monoamine oxidase Proteins 0.000 claims description 23
238000009472 formulation Methods 0.000 claims description 22
238000000034 method Methods 0.000 claims description 20
230000005764 inhibitory process Effects 0.000 claims description 13
229910052739 hydrogen Inorganic materials 0.000 claims description 12
239000001257 hydrogen Substances 0.000 claims description 12
239000003814 drug Substances 0.000 claims description 8
229940079593 drug Drugs 0.000 claims description 7
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
SKTDSCHBBJQCDE-UHFFFAOYSA-N 1-phenoxathiin-1-ylethanol Chemical compound O1C2=CC=CC=C2SC2=C1C=CC=C2C(O)C SKTDSCHBBJQCDE-UHFFFAOYSA-N 0.000 claims description 6
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
241000282412 Homo Species 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
239000000126 substance Substances 0.000 claims description 5
ZETFADRORWAXBD-UHFFFAOYSA-N 1-(10,10-dioxophenoxathiin-1-yl)ethanol Chemical compound O1C2=CC=CC=C2S(=O)(=O)C2=C1C=CC=C2C(O)C ZETFADRORWAXBD-UHFFFAOYSA-N 0.000 claims description 4
239000002775 capsule Substances 0.000 claims description 4
PKTQHXZCHYIMFP-UHFFFAOYSA-N 1-(10,10-dioxophenoxathiin-1-yl)ethane-1,2-diol Chemical compound O1C2=CC=CC=C2S(=O)(=O)C2=C1C=CC=C2C(O)CO PKTQHXZCHYIMFP-UHFFFAOYSA-N 0.000 claims description 3
AVCGPZJJCGYEDQ-UHFFFAOYSA-N 1-phenoxathiin-1-ylethane-1,2-diol Chemical compound O1C2=CC=CC=C2SC2=C1C=CC=C2C(O)CO AVCGPZJJCGYEDQ-UHFFFAOYSA-N 0.000 claims description 3
230000001430 anti-depressive effect Effects 0.000 claims description 3
238000002156 mixing Methods 0.000 claims description 3
XJLRCPYQIPAQCA-UHFFFAOYSA-N phenoxathiine 10,10-dioxide Chemical compound C1=CC=C2S(=O)(=O)C3=CC=CC=C3OC2=C1 XJLRCPYQIPAQCA-UHFFFAOYSA-N 0.000 claims description 3
UALGAWZECPBKOD-UHFFFAOYSA-N 1-(10,10-dioxophenoxathiin-1-yl)ethanone Chemical compound O1C2=CC=CC=C2S(=O)(=O)C2=C1C=CC=C2C(=O)C UALGAWZECPBKOD-UHFFFAOYSA-N 0.000 claims description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
229910052799 carbon Inorganic materials 0.000 claims description 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
239000002552 dosage form Substances 0.000 claims description 2
238000007911 parenteral administration Methods 0.000 claims description 2
241000124008 Mammalia Species 0.000 claims 7
210000005171 mammalian brain Anatomy 0.000 claims 3
OKEITXXEAYZCOA-UHFFFAOYSA-N 1-ethenylphenoxathiine 10,10-dioxide Chemical compound O1C2=CC=CC=C2S(=O)(=O)C2=C1C=CC=C2C=C OKEITXXEAYZCOA-UHFFFAOYSA-N 0.000 claims 2
230000002401 inhibitory effect Effects 0.000 claims 2
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
FVPFHLLCMSZVDO-UHFFFAOYSA-N 2-phenoxathiin-1-ylethanol Chemical compound O1C2=CC=CC=C2SC2=C1C=CC=C2CCO FVPFHLLCMSZVDO-UHFFFAOYSA-N 0.000 claims 1
239000000825 pharmaceutical preparation Substances 0.000 claims 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 28
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 26
239000004480 active ingredient Substances 0.000 description 22
239000000243 solution Substances 0.000 description 19
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
238000002844 melting Methods 0.000 description 14
230000008018 melting Effects 0.000 description 14
229960003732 tyramine Drugs 0.000 description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 12
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
239000007787 solid Substances 0.000 description 10
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
235000019441 ethanol Nutrition 0.000 description 9
239000002904 solvent Substances 0.000 description 9
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
229920002261 Corn starch Polymers 0.000 description 8
238000004458 analytical method Methods 0.000 description 8
210000004556 brain Anatomy 0.000 description 8
239000008120 corn starch Substances 0.000 description 8
229940099112 cornstarch Drugs 0.000 description 8
239000008187 granular material Substances 0.000 description 8
239000000758 substrate Substances 0.000 description 8
238000003556 assay Methods 0.000 description 7
235000019359 magnesium stearate Nutrition 0.000 description 7
229910052757 nitrogen Inorganic materials 0.000 description 7
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 6
230000000694 effects Effects 0.000 description 6
GJSGGHOYGKMUPT-UHFFFAOYSA-N phenoxathiine Chemical compound C1=CC=C2OC3=CC=CC=C3SC2=C1 GJSGGHOYGKMUPT-UHFFFAOYSA-N 0.000 description 6
239000000047 product Substances 0.000 description 6
229940076279 serotonin Drugs 0.000 description 6
239000003826 tablet Substances 0.000 description 6
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 5
241000700159 Rattus Species 0.000 description 5
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
150000004985 diamines Chemical class 0.000 description 5
239000007788 liquid Substances 0.000 description 5
239000000463 material Substances 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
238000005160 1H NMR spectroscopy Methods 0.000 description 4
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
229920000168 Microcrystalline cellulose Polymers 0.000 description 4
RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 4
BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 4
230000036772 blood pressure Effects 0.000 description 4
235000011089 carbon dioxide Nutrition 0.000 description 4
NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 4
238000004440 column chromatography Methods 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
239000010410 layer Substances 0.000 description 4
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
239000008108 microcrystalline cellulose Substances 0.000 description 4
235000019813 microcrystalline cellulose Nutrition 0.000 description 4
229940016286 microcrystalline cellulose Drugs 0.000 description 4
229960000964 phenelzine Drugs 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
239000002002 slurry Substances 0.000 description 4
238000003756 stirring Methods 0.000 description 4
239000000725 suspension Substances 0.000 description 4
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
208000019901 Anxiety disease Diseases 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
229960000583 acetic acid Drugs 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000000969 carrier Substances 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
239000011248 coating agent Substances 0.000 description 3
238000000576 coating method Methods 0.000 description 3
235000013305 food Nutrition 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
150000002431 hydrogen Chemical group 0.000 description 3
239000008101 lactose Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
230000036584 pressor response Effects 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
239000002511 suppository base Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
WCVOGSZTONGSQY-UHFFFAOYSA-N 2,4,6-trichloroanisole Chemical compound COC1=C(Cl)C=C(Cl)C=C1Cl WCVOGSZTONGSQY-UHFFFAOYSA-N 0.000 description 2
WIDLMPSIFONHNH-UHFFFAOYSA-N 2-(10,10-dioxophenoxathiin-1-yl)ethanol Chemical compound O1C2=CC=CC=C2S(=O)(=O)C2=C1C=CC=C2CCO WIDLMPSIFONHNH-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 2
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
208000027559 Appetite disease Diseases 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
208000019454 Feeding and Eating disease Diseases 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical class OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
206010019233 Headaches Diseases 0.000 description 2
208000019695 Migraine disease Diseases 0.000 description 2
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
238000005481 NMR spectroscopy Methods 0.000 description 2
229920002556 Polyethylene Glycol 300 Chemical class 0.000 description 2
229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
IMNFDUFMRHMDMM-UHFFFAOYSA-N anhydrous n-heptane Natural products CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
208000022531 anorexia Diseases 0.000 description 2
230000036506 anxiety Effects 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000004872 arterial blood pressure Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
239000011162 core material Substances 0.000 description 2
206010061428 decreased appetite Diseases 0.000 description 2
RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
239000000284 extract Substances 0.000 description 2
235000019253 formic acid Nutrition 0.000 description 2
239000000499 gel Substances 0.000 description 2
125000005456 glyceride group Chemical group 0.000 description 2
231100000869 headache Toxicity 0.000 description 2
239000008240 homogeneous mixture Substances 0.000 description 2
238000011534 incubation Methods 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
229940050176 methyl chloride Drugs 0.000 description 2
206010027599 migraine Diseases 0.000 description 2
239000002899 monoamine oxidase inhibitor Substances 0.000 description 2
239000012452 mother liquor Substances 0.000 description 2
238000000465 moulding Methods 0.000 description 2
230000004118 muscle contraction Effects 0.000 description 2
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
238000000746 purification Methods 0.000 description 2
LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
238000010992 reflux Methods 0.000 description 2
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000000829 suppository Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
IWYDHOAUDWTVEP-SSDOTTSWSA-N (R)-mandelic acid Chemical compound OC(=O)[C@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-SSDOTTSWSA-N 0.000 description 1
IWYDHOAUDWTVEP-ZETCQYMHSA-N (S)-mandelic acid Chemical compound OC(=O)[C@@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-ZETCQYMHSA-N 0.000 description 1
PONXTPCRRASWKW-UHFFFAOYSA-N 1,2-diphenylethane-1,2-diamine Chemical compound C=1C=CC=CC=1C(N)C(N)C1=CC=CC=C1 PONXTPCRRASWKW-UHFFFAOYSA-N 0.000 description 1
BTEZUKYLHAJTPM-UHFFFAOYSA-N 1-phenoxathiin-1-ylethanone Chemical compound O1C2=CC=CC=C2SC2=C1C=CC=C2C(=O)C BTEZUKYLHAJTPM-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
240000008025 Alternanthera ficoidea Species 0.000 description 1
241000282994 Cervidae Species 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
241000408495 Iton Species 0.000 description 1
101100531623 Mus musculus Rsbn1 gene Proteins 0.000 description 1
208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
206010033664 Panic attack Diseases 0.000 description 1
229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
229920003110 Primojel Polymers 0.000 description 1
101710121933 Prolactin-3B1 Proteins 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical class [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
JBBYCBXVYZDRPE-PSXMRANNSA-N [(2r)-2-[12-(2-azido-4-nitroanilino)dodecanoyloxy]-3-tetradecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCNC1=CC=C([N+]([O-])=O)C=C1N=[N+]=[N-] JBBYCBXVYZDRPE-PSXMRANNSA-N 0.000 description 1
XYDIMLHXEDSIDM-UHFFFAOYSA-N [Li]c1cccc2Oc3ccccc3S(=O)(=O)c12 Chemical compound [Li]c1cccc2Oc3ccccc3S(=O)(=O)c12 XYDIMLHXEDSIDM-UHFFFAOYSA-N 0.000 description 1
IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
239000012491 analyte Substances 0.000 description 1
229940082992 antihypertensives mao inhibitors Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
208000025748 atypical depressive disease Diseases 0.000 description 1
239000000022 bacteriostatic agent Substances 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000000035 biogenic effect Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
229910000085 borane Inorganic materials 0.000 description 1
208000030963 borderline personality disease Diseases 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
150000001722 carbon compounds Chemical class 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
235000013351 cheese Nutrition 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
229940125904 compound 1 Drugs 0.000 description 1
229940125782 compound 2 Drugs 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000000748 compression moulding Methods 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000003001 depressive effect Effects 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000007919 dispersible tablet Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
241000411851 herbal medicine Species 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
235000003642 hunger Nutrition 0.000 description 1
150000004678 hydrides Chemical class 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
239000011872 intimate mixture Substances 0.000 description 1
239000013038 irreversible inhibitor Substances 0.000 description 1
238000002955 isolation Methods 0.000 description 1
229940080428 lactose 200 mg Drugs 0.000 description 1
125000005647 linker group Chemical group 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229940057948 magnesium stearate Drugs 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
FBBDOOHMGLLEGJ-UHFFFAOYSA-N methane;hydrochloride Chemical compound C.Cl FBBDOOHMGLLEGJ-UHFFFAOYSA-N 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
230000002438 mitochondrial effect Effects 0.000 description 1
239000012046 mixed solvent Substances 0.000 description 1
239000007932 molded tablet Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000002969 morbid Effects 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
QEHKBHWEUPXBCW-UHFFFAOYSA-N nitrogen trichloride Chemical compound ClN(Cl)Cl QEHKBHWEUPXBCW-UHFFFAOYSA-N 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
239000012285 osmium tetroxide Substances 0.000 description 1
229910000489 osmium tetroxide Inorganic materials 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
208000019906 panic disease Diseases 0.000 description 1
JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
208000022821 personality disease Diseases 0.000 description 1
208000019899 phobic disease Diseases 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
208000028173 post-traumatic stress disease Diseases 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
239000001944 prunus armeniaca kernel oil Substances 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
238000011552 rat model Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
239000013037 reversible inhibitor Substances 0.000 description 1
238000009738 saturating Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000000707 stereoselective effect Effects 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
UORVGPXVDQYIDP-UHFFFAOYSA-N trihydridoboron Substances B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 1
239000000052 vinegar Substances 0.000 description 1
235000021419 vinegar Nutrition 0.000 description 1
239000003039 volatile agent Substances 0.000 description 1
239000007762 w/o emulsion Substances 0.000 description 1
238000010792 warming Methods 0.000 description 1
239000003643 water by type Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
- C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
- C07D327/06—Six-membered rings
- C07D327/08—[b,e]-condensed with two six-membered carbocyclic rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

JP3515263A 1990-09-17 1991-09-16 抗うつ剤としての１−置換フェノキサチイン誘導体 Pending JPH06500994A (ja)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US58391690A	1990-09-17	1990-09-17
US583,916		1990-09-17
GB919118955A GB9118955D0 (en)	1991-09-05	1991-09-05	Pharmacologically active compounds
GB9118955.5		1991-09-05

Publications (1)

Publication Number	Publication Date
JPH06500994A true JPH06500994A (ja)	1994-01-27

Family

ID=26299495

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP3515263A Pending JPH06500994A (ja)	1990-09-17	1991-09-16	抗うつ剤としての１−置換フェノキサチイン誘導体

Country Status (9)

Country	Link
EP (1)	EP0550518A1 (fr)
JP (1)	JPH06500994A (fr)
KR (1)	KR930701997A (fr)
AU (1)	AU8635691A (fr)
CA (1)	CA2091685A1 (fr)
IE (1)	IE913256A1 (fr)
IL (1)	IL99494A0 (fr)
PT (1)	PT98982A (fr)
WO (1)	WO1992004897A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2265943A1 (fr) *	1996-09-11	1998-03-26	Morton Harfenist	Composes constituant pharmacologiquement des principes actifs et leur utilisation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1447032A (en) *	1972-05-19	1976-08-25	Wellcome Found	Tricyclic sulphones and pharmaceutical compositions containing them
US4012517A (en) *	1975-01-24	1977-03-15	Burroughs Wellcome Co.	Compositions and treatment
EP0150891A1 (fr) *	1984-01-05	1985-08-07	The Wellcome Foundation Limited	Composés tricycliques, procédés pour leur préparation, compositions les contenant et leur usage en médecine
GB8921069D0 (en) *	1989-09-18	1989-11-01	Wellcome Found	Pharmaceutically active compound,preparation and use

1991
- 1991-09-16 KR KR1019930700784A patent/KR930701997A/ko not_active Withdrawn
- 1991-09-16 CA CA002091685A patent/CA2091685A1/fr not_active Abandoned
- 1991-09-16 AU AU86356/91A patent/AU8635691A/en not_active Abandoned
- 1991-09-16 JP JP3515263A patent/JPH06500994A/ja active Pending
- 1991-09-16 PT PT98982A patent/PT98982A/pt not_active Application Discontinuation
- 1991-09-16 IE IE325691A patent/IE913256A1/en unknown
- 1991-09-16 EP EP91916647A patent/EP0550518A1/fr not_active Withdrawn
- 1991-09-16 IL IL99494A patent/IL99494A0/xx unknown
- 1991-09-16 WO PCT/GB1991/001582 patent/WO1992004897A1/fr not_active Ceased

Also Published As

Publication number	Publication date
KR930701997A (ko)	1993-09-08
AU8635691A (en)	1992-04-15
IE913256A1 (en)	1992-02-25
CA2091685A1 (fr)	1992-03-18
EP0550518A1 (fr)	1993-07-14
WO1992004897A1 (fr)	1992-04-02
IL99494A0 (en)	1992-08-18
PT98982A (pt)	1993-11-30

Publication	Publication Date	Title
FI77018B (fi)	1988-09-30	Analogifoerfarande foer framstaellning av antidepressivt aktiv (-)-enantiomer av n-metyl-n-/3-(2-metylfenoxi) -3-fenylpropyl/amin och dess farmaceutiskt godtagbara salt.
JP6328170B2 (ja)	2018-05-23	治療化合物
EP4606798A1 (fr)	2025-08-27	Composé de benzoisothiazole, composition pharmaceutique et utilisation associée
KR20050043776A (ko)	2005-05-11	거울상 이성질체로 농축된, 시탈로프람의 데스메틸 및디데스메틸 대사물을 이용한 우울증 및 다른 중추신경계질환 치료방법
CN103360342B (zh)	2015-12-16	3-氰基苯胺烷基芳基哌嗪衍生物及在制备药物中的应用
CA2022236A1 (fr)	1991-02-01	Derives de coumarin, leur preparation et leur utilisation pour le traitement des troubles cerebrovasculaires
JPH04503074A (ja)	1992-06-04	リポキシゲナーゼ阻止化合物
JPH05506012A (ja)	1993-09-02	中枢神経系障害治療用含窒素シクロヘテロシクロアルキルアミノアリール誘導体
JPS58164583A (ja)	1983-09-29	フエノキシプロパノ−ルアミン誘導体
JPH06500994A (ja)	1994-01-27	抗うつ剤としての１−置換フェノキサチイン誘導体
CN104860847B (zh)	2017-06-27	利凡斯的明和咖啡酸、阿魏酸的二聚体,其制备方法及其药物组合物
US4107303A (en)	1978-08-15	Antihypertensive hexafluorohydroxyisopropyl benzazepines and benzazocines
KR940000074B1 (ko)	1994-01-05	약리적으로 활성인 화합물, 그 제법 및 그 용도
JP2005538146A (ja)	2005-12-15	新規なピペリジン―２，６−ジオンパモエート塩類及びストレス関連情動性疾患を治療・処置するためにこれらを使用する方法
US4868315A (en)	1989-09-19	Novel aryloxycycloalkanolaminoalkylene aryl ketones
US4499087A (en)	1985-02-12	7-Phenyl-7-phenoxymethyl-hexahydro-1,4-oxazepines and their use
JP2565543B2 (ja)	1996-12-18	イソオキサゾール化合物およびその用途
JPS6242965A (ja)	1987-02-24	飽和シクロアルキル〔ｂ〕ピロ−ル−１（２Ｈ）−酢酸アミドおよびその誘導体
RU2002738C1 (ru)	1993-11-15	Способ получени производных N-гидроксимочевин в виде R- или S-энантиомерных форм или их смеси, или их фармацевтически приемлемых солей с щелочным металлом
US5216028A (en)	1993-06-01	Therapeutic uses of a diphenylsulfide compound to treat depression and effect serotonin uptake
JPS63253055A (ja)	1988-10-20	ヒドロフルオレン誘導体
JPH04108730A (ja)	1992-04-09	アレルギー性疾患治療剤
JPS62207244A (ja)	1987-09-11	含窒素テルペンアルコ−ル類及びこれを有効成分とする抗アレルギ−剤